東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Cardio-oncology = management of toxi...

Russo, Antonio.

Linked to FindBook

Google Book

Amazon

博客來

Cardio-oncology = management of toxicities in the era of immunotherapy /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Cardio-oncology/ edited by Antonio Russo ... [et al.].
Reminder of title:	management of toxicities in the era of immunotherapy /
other author:	Russo, Antonio.
Published:	Cham :Springer International Publishing : : 2022.,
Description:	xiv, 122 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.
Contained By:	Springer Nature eBook
Subject:	Cancer - Immunotherapy -
Online resource:	https://doi.org/10.1007/978-3-030-97744-3
ISBN:	9783030977443

Cardio-oncology = management of toxicities in the era of immunotherapy /
Cardio-oncologymanagement of toxicities in the era of immunotherapy /[electronic resource] :edited by Antonio Russo ... [et al.]. - Cham :Springer International Publishing :2022. - xiv, 122 p. :ill. (some col.), digital ;24 cm. - Current clinical pathology,2197-7828. - Current clinical pathology..

1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.

The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC) This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.

ISBN: 9783030977443

Standard No.: 10.1007/978-3-030-97744-3doiSubjects--Topical Terms:

3604761
Cancer
--Immunotherapy

LC Class. No.: RC271.I45 / C37 2022

Dewey Class. No.: 616.994061

Cardio-oncology = management of toxicities in the era of immunotherapy /
LDR:03136nmm a2200325 a 4500 001 2303460
003 DE-He213
005 20220809083351.0
007 cr nn 008maaau
008 230409s2022 sz s 0 eng d
020 $a 9783030977443 $q (electronic bk.)
020 $a 9783030977436 $q (paper)
024 7 $a 10.1007/978-3-030-97744-3 $2 doi
035 $a 978-3-030-97744-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45 $b C37 2022
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994061 $2 23
090 $a RC271.I45 $b C267 2022
245 0 0 $a Cardio-oncology $h [electronic resource] : $b management of toxicities in the era of immunotherapy / $c edited by Antonio Russo ... [et al.].
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2022.
300 $a xiv, 122 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Current clinical pathology, $x 2197-7828
505 0 $a 1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.
520 $a The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC) This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.
650 0 $a Cancer $x Immunotherapy $x Complications. $3 3604761
650 0 $a Cardiovascular toxicology. $3 891186
650 1 4 $a Oncology. $3 751006
650 2 4 $a Cardiology. $3 861477
650 2 4 $a Pathology. $3 643180
650 2 4 $a Internal Medicine. $3 858559
700 1 $a Russo, Antonio. $3 1566800
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Current clinical pathology. $3 1566803
856 4 0 $u https://doi.org/10.1007/978-3-030-97744-3
950 $a Medicine (SpringerNature-11650)